Boston Scientific has signed an investment agreement with privately held medical device company Farapulse with an exclusive option for acquisition.
The financial details of the deal were not disclosed.
Farapulse develops pulsed-field ablation (PFA) system to treat atrial fibrillation (AF) and other cardiac arrhythmias.
The PFA system, which consists of a sheath, generator and catheters, is designed to ablate heart tissue by forming a therapeutic electric field instead of using thermal energy sources, including radiofrequency ablation or cryoablation.
